| Sign In to gain access to subscriptions and/or personal tools. |
Pharmacokinetic Interaction Between Indoramin and EthanolDepartment of Clinical Pharmacology, St Bartholomew's Hospital, London, EC1A 7BE
Drug Metabolism and Pharmacokinetics Section, Wyeth Research (UK) Ltd., Huntercombe Lane South, Taplow, Maidenhead, Berks, SL6 OPH, UK
Department of Clinical Pharmacology, St Bartholomew's Hospital, London, EC1A 7BE
Department of Clinical Pharmacology, St Bartholomew's Hospital, London, EC1A 7BE
Drug Metabolism and Pharmacokinetics Section, Wyeth Research (UK) Ltd., Huntercombe Lane South, Taplow, Maidenhead, Berks, SL6 OPH, UK
Department of Clinical Pharmacology, St Bartholomew's Hospital, London, EC1A 7BE 1 The effect of ethanol consumption (0.5 g/kg) on the pharmacokinetics of the alpha adrenoceptor antagonist indoramin, administered orally (50 mg) or intravenously (0.175 mg/kg) has been investigated in young volunteers. Sedation was also assessed using a visual analogue scale. 2 After oral indoramin administration, ethanol caused increases of 58% (P <0.01) in CPmax , and 25% (P <0.05) in AUC. There was no effect of alcohol on elimination half-life. The combination of ethanol and indoramin was more sedative than indoramin alone. 3 Ethanol did not alter the pharmacokinetics of an intravenous dose of indoramin. However indoramin caused a small but statistically significant increase (26%) in blood ethanol concentrations during the first 1.25 h after dosing. Both indoramin and ethanol caused sedation. 4 The increased bioavailability of oral indoramin in the presence of ethanol may reflect some enhanced absorption, but it is also consistent with inhibition of first-pass metabolism of a flow-limited drug. The clinical implications are discussed.
Human & Experimental Toxicology, Vol. 8, No. 3,
237-241 (1989) |
|||